Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van der Worp, H. B.
Right arrow Articles by van Gijn, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van der Worp, H. B.
Right arrow Articles by van Gijn, J.
Related Collections
Right arrow CT
Right arrow All Clinical trials
Right arrow Infarction
Neurology 2002;58:133-135
© 2002 American Academy of Neurology
Brief Communications

The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke

H. B. van der Worp, MD PhD;, L. J. Kappelle, MD PhD;, A. Algra, MD PhD;, P. R. Bär, PhD, J. M. Orgogozo, MD, E. B. Ringelstein, MD, P. M.W. Bath, MD PRCP; and J. van Gijn, MD FRCP on behalf of the TESS and TESS II Investigators

From the Department of Neurology (Drs. van der Worp, Kappelle, Algra, Bär, and van Gijn) and the Julius Center for Patient-Oriented Research (Dr. Algra), University Medical Center, Utrecht, the Netherlands; the Department of Neurology (Dr. Orgogozo), Groupe Hospitalier Pellegrin, Bordeaux, France; the Department of Neurology (Dr. Ringelstein), Westfälische Wilhelms–Universität, Münster, Germany; and the Division of Stroke Medicine (Dr. Bath), University of Nottingham, United Kingdom.

Address correspondence and reprint requests to Dr. H.B. van der Worp, Department of Neurology, HP G 03.228, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, the Netherlands; e-mail: h.b.vandeworp{at}neuro.azu.nl

The authors investigated whether the lack of effect of tirilazad on clinical outcome in patients with acute ischemic stroke is explained by failure of tirilazad to reduce infarct volume. Overall, tirilazad had no significant effect on infarct volume. In the subgroups of male patients and of those with a cortical infarct, tirilazad significantly reduced infarct volume. These effects were reduced to nonsignificant trends after adjustment for imbalances in baseline characteristics. In conclusion, early treatment of patients with tirilazad has no effect on infarct volume.




This article has been cited by other articles:


Home page
 StrokeHome page
M. D. Ginsberg
Life After Cerovive: A Personal Perspective on Ischemic Neuroprotection in the Post-NXY-059 Era
Stroke, June 1, 2007; 38(6): 1967 - 1972.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.